Angle PLC Shares Rise on Cancer Patient Blood Sample Analysis
By Ian Walker
Angle PLC shares rose as much as 41% in early trade after the company said that DNA molecular analysis from cancer patient blood samples provides insight into the progression and treatment of cancers for those patients, and enables it to expand product sales and pharmaceutical service offerings.
Shares at 0834 GMT were up 4.50 pence, or 34%, at 17.75 pence having peaked at 18.63 pence earlier in the session. However, they are down 63% over the past 12 months.
The U.K. liquid-biopsy company said Thursday that the results come from 47 patient samples in breast, lung, prostate and ovarian cancers.
"Today's breakthrough is the critical next step post the [Food and Drug Administration] clearance to show in a sample-to-answer format the potential clinical value of NGS [next generation sequencing] molecular analysis on a repeat basis of living cancer cells harvested from patient blood samples," Chief Executive Officer Andrew Newland said.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
January 04, 2024 03:55 ET (08:55 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom
-
Albemarle Earnings: We Expect Improved Results In the Rest of Year Following Cyclically Low Profits